Industry News (Patents and Technologies)

Patent Issuance on Neurodegenerative Diseases Treatment Announced

Published in Gene Therapy Weekly, October 19th, 1998

NeoTherapeutics, Inc., Irvine, California, announced that the company has been issued a U.S. patent on gene regulation technology involved in treating neurodegenerative diseases.

The U.S. patent describes how purine derivatives, a class of drug compounds which includes Neotrofin (AIT-082, leteprinim potassium), can be used to selectively control "turning on or off of genes" for the protein molecules involved in nerve regeneration.

This patent represents a significant step forward in the treatment of neurodegenerative diseases utilizing a convenient oral medication to replace or augment the presence of neurotrophic factors in the brain and spinal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry